troglitazone has been researched along with bortezomib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brauer, KM; Bringmann, A; Brossart, P; Held, SA; Schaub, A; von Schwarzenberg, K | 1 |
| Bigley, V; Collin, M; Hambleton, S; Jardine, L; Pagan, S; Wang, XN | 1 |
1 review(s) available for troglitazone and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for troglitazone and bortezomib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Chromans; Cytokines; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Mitogen-Activated Protein Kinases; NF-kappa B; PPAR gamma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thiazolidinediones; Troglitazone | 2009 |
Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.
Topics: Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Chromans; Humans; Killer Cells, Natural; Ligands; NK Cell Lectin-Like Receptor Subfamily K; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Thiazolidinediones; Troglitazone; Up-Regulation; Valproic Acid | 2013 |